Drugs / FRSW117
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04864743 | Jun → Oct 2021 | severe hemophilia A | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05265286 | Apr → Aug 2022 | severe hemophilia A | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06142552 | Dec 2023 → Oct 2025 | severe hemophilia A | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRSW117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04864743 ↗ |
| Modality | Protein / enzyme biologic | “PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection” NCT04864743 ↗ |